2017•Nigerian Journal of Gastroenterology and HepatologyRequires access

Diagnostic accuracy of FIB-4, APRI and AST/ALT ratio for prediction of fibrosis in chronic hepatitis B and C patients

D.M. Nisar A. Shah, Showkat Ahmad Kadla, Irfan Ahmad Mir, Bilal Ahmad Khan, Asif Iqbal Shah, Shabir Ahmad Shiekh, Khalid Javed Bhat

Open publisher page 0 citations

Abstract

Background and Objectives: Accurate assessment of liver fibrosis is essential for successful disease management for people with chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Although liver biopsy remains gold standard for diagnosis of liver fibrosis, it has some limitations. To overcome these limitations multiple noninvasive modalities have been introduced. The main aim of our study was to validate the various fibrosis scoring systems with liver biopsy and give recommendations to replace it with these scoring systems if feasible in hepatitis B and C.Methods: We included 62 patients, 32 (51.60%) had hepatitis B, and 30 (48.40%) had hepatitis C infection. These patients were enrolled from Out Patient Department and In Patient Department of Sri Maharaja Hari Singh Hospital, Srinagar. We examined the validity of commonly used liver fibrosis scoring systems: FIB-4 (Fibrosis-4 Index), APRI (Aspartate aminotransferase to Platelet Ratio) and AST (Aspartate Aminotransferase)/ ALT(Alanine Aminotransferase) ratio. Liver biopsy was histologically graded using Knodell, Ishak and Metavir grading systems. On basis of histopathological examination, the patients were divided into those with non-significant fibrosis (F0-F2) and significant fibrosis (F3-F4); and those without cirrhosis (F0-F3) and with cirrhosis (F4).Results: In case of CHB patients, all 32(100%) belonged to non-significant fibrosis group (F0-F2) and none had cirrhosis. In case of CHC, 12(40%) patients had insignificant fibrosis while as 18(60%) had fibrosis to cirrhosis. The sensitivity and specificity of FIB-4 in detecting significant fibrosis was 91.7% and 88.9% respectively. For cirrhosis, these parameters were 100% and 81.8% respectively. The sensitivity and specificity of APRI in detecting significant fibrosis was 75% and 91.4% respectively and for cirrhosis, 87.5% and 82.4% respectively. The sensitivity and specificity of AST/ALT ratio in detecting significant fibrosis was 50% and 83.9% while for cirrhosis, 57.5% and 80.9% respectively.Conclusion: Our study suggests that FIB-4 and APRI are excellent surrogate markers for liver fibrosis, ASL/ALT is not a very sensitive marker. Among all, FIB-4 fared the best.Keywords: Liver fibrosis, Non-invasive methods, Liver biopsy, Hepatitis B, Hepatitis C

About this research paper

What this paper is about

Background and Objectives: Accurate assessment of liver fibrosis is essential for successful disease management for people with chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Although liver biopsy remains gold standard for diagnosis of liver fibrosis, it has some limitations. To overcome these limitations multiple noninvasive modalities have been introduced. The main aim of our study was to validate the various fibrosis scoring systems with liver biopsy and give recommendations to replace it with these scoring systems if feasible in hepatitis B and C.Methods: We included 62 patients, 32 (51.60%) had hepatitis B, and 30 (48.40%) had hepatitis C infection. These patients were enrolled from Out Patient Department and In Patient Department of Sri Maharaja Hari Singh Hospital, Srinagar. We examined the validity of commonly used liver fibrosis scoring systems: FIB-4 (Fibrosis-4 Index), APRI (Aspartate aminotransferase to Platelet Ratio) and AST (Aspartate Aminotransferase)/ ALT(Alanine Aminotransferase) ratio. Liver biopsy was histologically graded using Knodell, Ishak and Metavir grading systems. On basis of histopathological examination, the patients were divided into those with non-significant fibrosis (F0-F2) and significant fibrosis (F3-F4); and those without cirrhosis (F0-F3) and with cirrhosis (F4).Results: In case of CHB patients, all 32(100%) belonged to non-significant fibrosis group (F0-F2) and none had cirrhosis. In case of CHC, 12(40%) patients had insignificant fibrosis while as 18(60%) had fibrosis to cirrhosis. The sensitivity and specificity of FIB-4 in detecting significant fibrosis was 91.7% and 88.9% respectively. For cirrhosis, these parameters were 100% and 81.8% respectively. The sensitivity and specificity of APRI in detecting significant fibrosis was 75% and 91.4% respectively and for cirrhosis, 87.5% and 82.4% respectively. The sensitivity and specificity of AST/ALT ratio in detecting significant fibrosis was 50% and 83.9% while for cirrhosis, 57.5% and 80.9% respectively.Conclusion: Our study suggests that FIB-4 and APRI are excellent surrogate markers for liver fibrosis, ASL/ALT is not a very sensitive marker. Among all, FIB-4 fared the best.Keywords: Liver fibrosis, Non-invasive methods, Liver biopsy, Hepatitis B, Hepatitis C

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Background and Objectives: Accurate assessment of liver fibrosis is essential for successful disease management for people with chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Although liver biopsy remains gold standard for diagnosis of liver fibrosis, it has some limitations. To overcome these limitations multiple noninvasive modalities have been introduced. The main aim of our study was to validate the various fibrosis scoring systems with liver biopsy and give recommendations to replace it with these scoring systems if feasible in hepatitis B and C.Methods: We included 62 patients, 32 (51.60%) had hepatitis B, and 30 (48.40%) had hepatitis C infection. These patients were enrolled from Out Patient Department and In Patient Department of Sri Maharaja Hari Singh Hospital, Srinagar. We examined the validity of commonly used liver fibrosis scoring systems: FIB-4 (Fibrosis-4 Index), APRI (Aspartate aminotransferase to Platelet Ratio) and AST (Aspartate Aminotransferase)/ ALT(Alanine Aminotransferase) ratio. Liver biopsy was histologically graded using Knodell, Ishak and Metavir grading systems. On basis of histopathological examination, the patients were divided into those with non-significant fibrosis (F0-F2) and significant fibrosis (F3-F4); and those without cirrhosis (F0-F3) and with cirrhosis (F4).Results: In case of CHB patients, all 32(100%) belonged to non-significant fibrosis group (F0-F2) and none had cirrhosis. In case of CHC, 12(40%) patients had insignificant fibrosis while as 18(60%) had fibrosis to cirrhosis. The sensitivity and specificity of FIB-4 in detecting significant fibrosis was 91.7% and 88.9% respectively. For cirrhosis, these parameters were 100% and 81.8% respectively. The sensitivity and specificity of APRI in detecting significant fibrosis was 75% and 91.4% respectively and for cirrhosis, 87.5% and 82.4% respectively. The sensitivity and specificity of AST/ALT ratio in detecting significant fibrosis was 50% and 83.9% while for cirrhosis, 57.5% and 80.9% respectively.Conclusion: Our study suggests that FIB-4 and APRI are excellent surrogate markers for liver fibrosis, ASL/ALT is not a very sensitive marker. Among all, FIB-4 fared the best.Keywords: Liver fibrosis, Non-invasive methods, Liver biopsy, Hepatitis B, Hepatitis C

Key concepts: Cirrhosis, Medicine, Gastroenterology, Fibrosis, Liver biopsy, Internal medicine, Gold standard (test), Biopsy

Related papers

Back to paper searchBrowse research topicsOriginal source
Diagnostic accuracy of FIB-4, APRI and AST/ALT ratio for prediction of fibrosis in chronic hepatitis B and C patients — Research Paper | ScholarLens